|
Important Formulary Change Announcement
Magellan Rx recently made some important changes to its Hepatitis C products coverage. Specifically, as of January 1, 2016, Harvoni® and Sovaldi® will be the only preferred Hepatitis C agents on the formulary. Viekira Pak® will no longer be a preferred agent and will move to non-preferred status.
The Magellan Rx National Formulary is established by the practicing physicians and pharmacists who comprise its Pharmacy and Therapeutics (P&T) Committee. The P&T Committee reviews drugs based on their evaluation of evidence for efficacy, effectiveness and safety. The Value Assessment Committee (VAC) considers factors such as therapy alternatives, outcomes statistics, utilization metrics and cost.
Magellan Rx recognizes that patient-specific variables and other factors must be taken into account in determining whether a particular prescription product is medically appropriate for a specific patient; they also recognize that physicians ultimately make that decision. For patients in whom Harvoni or Sovaldi are inappropriate, Magellan Rx has a process in place to obtain a formulary exception for other available products.
Review the full Magellan Rx formulary here.
| 
